OGEN

Oragenics

• TipRanks·03/31 23:45

  Oragenics Sets New 2025 Annual Shareholder Meeting Date

• TipRanks·03/17 12:49

  Oragenics files annual report on Form 10-K

• NASDAQ·03/12 14:30

  Oragenics Kick Off Phase IIa Trial Operations For ONP-002; Stock Up

• Benzinga·03/12 12:38

  Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia

• TipRanks·03/12 01:49

  Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions

• TipRanks·03/11 12:45

  Oragenics explores potential acquisition of additional assets in CNS space

• Benzinga·03/11 12:42

  Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed

• TipRanks·03/10 12:42

  Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

• Benzinga·03/10 12:33

  Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment

• TipRanks·02/09 13:46

  Oragenics previews targeted milestones for 2026

• Benzinga·02/09 13:38

  Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI

• TipRanks·02/03 13:40

  Oragenics partners with Duck Flats Pharma to support FDA IND trial design

• Benzinga·02/03 13:35

  Oragenics Engages DUCK FLATS Pharma As It U.S. Investigational New Drug Readiness, Regulatory Execution Partner To Support FDA-Facing Preparation, Clinical Study Design

• Benzinga·01/28 21:05

  12 Health Care Stocks Moving In Wednesday's After-Market Session

• TipRanks·01/22 21:36

  Oragenics Extends At-the-Market Equity Sales Agreement